IL5 and chronic rhinosinusitis with nasal polyps: In patients with CRSwNP, a single intravenous infusion of reslizumab reduced the size of nasal polyps for 4 weeks in half of the patients with nasal IL-5 levels predicting the response, decreased nasal ECP levels persisted for 12 weeks only in responders [226].